Simply AmazingI looked at the 1 year chart, Arch is down 15% from a year ago, the share price if 15% lower.
How can that be considering all the progress we have made from be able to dose at mucher higher rate, We had third party independcrevuew published on phase 2 Lung trial. We received FDA approval for phase 2 AKI trial have 9 sites between Turkey & Canada. We had Pre-IND discussions with FDA to commence another phase 2 trial with our re-purposed drug Cilastatin to commence trial in Fall of 2024.
Makes no sense but presents a huge buying opportunity for those who have dry powder!